PDCD1 and small cell lung carcinoma: Of the 12 patients with SCLC from two ongoing phase II trials (NCT04539977 and NCT04542369) who received neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy, five had major pathologic response (MPR) and seven had non-MPR.